BioCentury | Jun 16, 2020
Finance

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

The series B round for eTheRNA will fund the Belgian company’s core immuno-oncology pipeline as well as its different mRNA approach to combat the threat of coronaviruses. eTheRNA immunotherapies N.V. said Tuesday it raised €34...
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

With its largest venture and growth capital fund to date, a $450 million vehicle, Gilde Healthcare is the latest European VC seeking to take bigger stakes in start-ups than it previously had sought, sometimes investing...
BC Innovations | May 14, 2019
Distillery Therapeutics

TRPC6 inhibitor for cardiac and renal fibrosis

DISEASE CATEGORY: Cardiovascular; renal INDICATION: Cardiovascular; renal Cell culture and mouse studies identified a trifluoromethylphenyl-based TRPC6 inhibitor that could help treat cardiac and renal fibrosis. High throughput screening of a small molecule library in cell-based...
BC Week In Review | Jan 19, 2018
Financial News

HalioDx raises first tranche of €18.5M series B

Diagnostic company HalioDx S.A.S. (Marseille, France) raised €9.25 million ($11.3 million) on Jan. 17 in the first tranche of a €18.5 million ($22.6 million) series B round led by new investor PSIM. Other new investors...
BC Extra | Jan 17, 2018
Financial News

HalioDx raises first tranche of €18.5M series B

Diagnostic company HalioDx S.A.S. (Marseille, France) raised €9.25 million ($11.3 million) in the first tranche of a €18.5 million ($22.6 million) series B round led by new investor PSIM. Other new investors Quest for Growth...
BC Week In Review | Jul 28, 2017
Clinical News

Reata reports Phase II data for bardoxolone methyl in CKD

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported data from 30 patients with chronic kidney disease (CKD) caused by Alport syndrome in the open-label Phase II portion of the Phase II/III CARDINAL trial showing that once-daily oral bardoxolone...
BC Extra | Jul 24, 2017
Clinical News

Reata gains as bardoxolone study moves to Phase III

Reata Pharmaceuticals Inc. (NASDAQ:RETA) gained $4.37 (14%) to $35.47 on Monday after saying it will move ahead to the Phase III portion of the Phase II/III CARDINAL study of bardoxolone methyl ( RTA 402 ) to treat...
BC Extra | Apr 3, 2017
Company News

Ogeda takeout gives Astellas hot flashes candidate

Astellas Pharma Inc. (Tokyo:4503) is acquiring Ogeda S.A. (Gosselies, Belgium), giving the pharma neurokinin 3 receptor ( TACR3 ; NK3R) antagonist fezolinetant ( ESN364 ). The candidate has met the primary endpoints in a Phase IIa trial...
BC Week In Review | Mar 9, 2017
Financial News

Thermo Fisher completes private placement of senior notes

On March 7, life sciences supplier Thermo Fisher Scientific Inc. (NYSE:TMO) raised €500 million ($531.3 million) through the sale of 1.45% senior notes due in 2027. Credit Suisse Securities, HSBC Bank, BNP Paribas, Citigroup, Deutsche...
BC Week In Review | Dec 9, 2016
Financial News

Zimmer Biomet completes private placement of senior notes

Zimmer Biomet raised €1 billion ($1.1 billion) in senior unsecured notes comprising €500 million ($531.9 million) in 1.414% notes due in 2022 and €500 million in 2.425% notes due in 2026. BNP Paribas, HSBC, RBC...
Items per page:
1 - 10 of 331